Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
ASH 2019Some Patients with DLBCL Can Skip Radiation: 'It's a Win'A 'no radiation' approach may be possible for managing non-bulky (stage I/II) disease in patients with DLBCL. These patients may do well with just 4 cycles of R-CHOP after an interim PET-negative scan.
Medscape Medical News, December 8, 2019
ASH 2019An Off-the-Shelf Drug to Rival CAR T Cells: 'Very Exciting' A novel bispecific antibody, mosunetuzumab, has shown complete remissions in patients with poor prognosis non-Hodgkin's lymphoma, even those previously treated with CAR T cells.
Medscape Medical News, December 7, 2019
Meeting Highlights At A Glance
Top News From ASH 2019: SlideshowHighlights include the exciting prospect of an off-the-shelf product to rival CAR T cells, practice-changing studies on two
leukemias, plus 'Choosing Wisely' advice for children.
Four Cycles of CHOP Instead of Six for Favorable DLBCLPatients with favorable-prognosis DLBCL receiving four cycles of R-CHOP followed by two additional cycles of rituximab had
outcomes similar to those in patients receiving six cycles.
